Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)

NCT01085656 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT01085656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01085656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Lead sponsor
University of Florida
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2011
Completion date
January 31, 2016
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myelogenous, acute, myelodysplastic syndromes